Asia on track for gains, but what's next

Eleanor Creagh

Australian Market Strategist

Summary:  A mixed day in Asia as US futures decline, along with the USD.


Another mixed day in Asia, most of the region advancing following the recovery in risk after three consecutive days of gains sustained on Wall Street, whilst Aussie and Kiwi stocks follow US futures lower. ASX200 -4.70%, NZX50 -0.79%, KOSPI +0.47%, Hang Seng +1.21%, Shanghai +1.60%, Nikkei +2.01% at the time of writing. However, the bear market bounce puts the MSCI Asia Pacific index on track for its best week since 2011. The continued pullback in the USD as well as the unprecedented whatever it takes backstop from the Fed, anticipation of the $2trn US fiscal stimulus package and short covering all helping to lift equities off lows.

China today posted the biggest industrial profits fall on record, but the markets focus is elsewhere. The S&P 500 has now retraced 38.2% of its decline from mid-February, but with breadth and volume declining in the Thursday session relative to Wednesday. Whether quarter end rebalancing, stimulus optimism, or just the classic example of a vicious bear market rally following a violent sell-off, as we saw overnight with initial jobless claims all but cementing the path to recession posting in excess of 3mn, the market is in the mood to shrug off the data (for now!). Commodity markets however have not joined the party as copper trades lower along with crude oil. And as we said previously, there is a real disconnect between the real picture which is cascading unemployment, bankruptcy headlines and a true “bottom” in equities.

Meanwhile, the US has now surpassed China in confirmed COVID-19 cases and the immunologist, Dr Anthony Fauci, who serves as a voice of reason the White House Coronavirus task force states, “We are in the escalating phase of a very serious pandemic. That is a fact. We have got to realize that and to prepare and respond. It is not, as it were, under control. Because it's still going up.”

The US is still early on in the infection curve, and the recent rally in risk sentiment is at odds with this outlook. Rightly or wrongly, it is clear by now the markets are not just looking for stimulus measures, monetary and fiscal, to relieve the pressure on risk assets, the more pressing matter is the containment of the virus itself. Markets will not stabilise without the spread of the pandemic slowing with an eye to lockdowns being lifted. Ultimately, we do not yet know the scale of the problem and the task of estimating the depth and duration of the hit to economic growth and earnings is near on impossible at this stage. Even those best placed, the companies themselves have opted to withdraw guidance on earnings. Moreover, the dispersion in analyst and economists’ forecasts for the hit to EPS growth and GDP highlight the level of uncertainty that prevails. We are sceptical of a lasting relief rally until contagion under control, transmission rates reduced and the infection curve flattened. In addition, despite the record setting rally this week, with VIX at 61.00 (a ninth consecutive close above 60, unprecedented!) and VVIX at 169.6 it would be premature to sound the all clear.
Source: 6 figure invest

Shutdowns are becoming more broad-based in Europe and Asia and have the potential to last longer than is currently estimated, the underlying assumption is that shutdowns are lifted and activity bounces back by the 2H and there is no re-infection resulting in another round of shutdowns. Resurgent cases in HK and Singapore and extended containment measures, perhaps indicating that going all in on those assumptions right now is not wise.

Disclaimer

Saxo Capital Markets (Australia) Pty Ltd prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at https://www.home.saxo/en-au/legal/.

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

Please read our disclaimers:
- Full Disclaimer (https://www.home.saxo/en-au/legal/disclaimer/saxo-disclaimer)
- Analysis Disclaimer (https://www.home.saxo/en-au/legal/analysis-disclaimer/saxo-analysis-disclaimer)
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-au/about-us/awards

Saxo Capital Markets (Australia) Pty Ltd ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide and Product Disclosure Statement to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Trading in leveraged products such as CFDs and Margin FX products may result in your losses surpassing your initial deposits. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.
Please click here to view our full disclaimer.